Sanofi US and Sanofi-aventis Canada Inc. (Sanofi Canada) are voluntarily recalling all Auvi‑Q® and all Allerject® (epinephrine injection, USP). The products have been found to potentially have inaccurate dosage delivery. As of October 26, 2015, Sanofi US and Canada have received 26 reports of suspected device malfunctions from an estimated 2,784,000 units distributed in North America.
The recall involves all Auvi‑Q currently on the market and includes both the 0.15 mg and 0.3 mg strengths for hospitals, retailers and consumers. This includes lot number 2299596 through 3037230, which expire March 2016 through December 2016.
People with an Auvi‑Q device should immediately contact their healthcare providers for prescriptions for alternate epinephrine auto‑injectors. Details about reimbursement will be available on www.Auvi‑Q.com as soon as they are available.
Customers with questions regarding this recall can go to www.Auvi‑Q.com and call 1‑866‑726‑6340 Monday through Friday 8 a.m. to 8 p.m. ET for information about how to return their Auvi‑Q devices. Customers may also email [email protected] Sanofi US will provide reimbursement for out of pocket costs incurred for the purchase of new epinephrine auto‑injectors with proof of purchase.
For more details on the Auvi-Q Voluntary Recall, visit Auvi-Q.com
The voluntary recall involves all Allerject currently on the market and includes both the 0.15 mg/ 0.15 mL and 0.3 mg/0.3 mL strengths for hospitals, retailers and consumers.
Canadian customers are asked to immediately return the product to their local pharmacy to obtain an alternate epinephrine auto-injector. In the absence of availability of an alternate epinephrine auto-injector, patients are instructed to retain their Allerject device until an alternate auto-injector is available.
Any questions or concerns regarding this voluntary product recall, please contact the Allerject Call Center at 1-855-405-4321.
For more details on the Allerject Voluntary Nationwide Recall, visit sanofi.ca